# Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®

> **NCT04896853** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **NextCell Pharma Ab** · enrollment: 9 (estimated)

## Conditions studied

- COVID-19 Acute Respiratory Distress Syndrome
- Influenza A
- Metapneumovirus Pneumonia
- Respiratory Syncytial Virus (RSV)

## Interventions

- **BIOLOGICAL:** ProTrans®

## Key facts

- **NCT ID:** NCT04896853
- **Lead sponsor:** NextCell Pharma Ab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-18
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04896853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04896853, "Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04896853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*